Advertisement

Blood and Cerebrospinal Fluid Biomarkers in Vascular Dementia and Alzheimer’s Disease

A Brief Review
Published:October 18, 2022DOI:https://doi.org/10.1016/j.cger.2022.08.001

      Keywords

      To read this article in full you will need to make a payment

      Purchase one-time access:

      Academic & Personal: 24 hour online accessCorporate R&D Professionals: 24 hour online access
      One-time access price info
      • For academic or personal research use, select 'Academic and Personal'
      • For corporate R&D use, select 'Corporate R&D Professionals'

      Subscribers receive full online access to your subscription and archive of back issues up to and including 2002.

      Content published before 2002 is available via pay-per-view purchase only.

      Subscribe:

      Subscribe to Clinics in Geriatric Medicine
      Already a print subscriber? Claim online access
      Already an online subscriber? Sign in
      Institutional Access: Sign in to ScienceDirect

      References

        • Gorelick P.B.
        • Furie K.
        • Iadecola C.
        • et al.
        Defining optimal brain health in adults: a presidential advisory from the American Heart Association/American Stroke Association.
        Stroke. 2017; 48: e284-e303
        • Hachinski V.
        • Einhaupt K.
        • Ganten D.
        • et al.
        Preventing dementia by preventing stroke: the Berlin Manifesto.
        Alzheimer’s Dement. 2019; 15: 961-984
        • Sweeney M.D.
        • Mantagne A.
        • Sagre A.P.
        • et al.
        Vascular dysfunction—the disregarded partner of Alzheimer’s disease.
        Alzheimer’s Demen. 2019; 15: 158-167
        • Jack Jr., C.R.
        • Bennett D.A.
        • Blennow K.
        • et al.
        NIA-AA research framework: toward a biological definition of Alzheimer’s disease.
        Alzheimer’s Demen. 2018; 14: 535-562
        • Amur A.
        • FDA-NIH Biomarker Working Group
        (Available at:) (Accessed online, March 2022)
        • Gorelick P.B.
        Vascular cognitive impairment (Chapter 6).
        in: Lazar R.M. Pavol M.A. Browndyke J.N. Neurovascular neuropsychology. 2nd edition. Springer, Cham, Switzerland2020: 121-138
        • Rosenberg G.A.
        • Kornfeld M.
        • Storving J.
        • et al.
        Subcortical arteriosclerotic encephalopathy (Binswanger): computerized tomography.
        Neurology. 1979; 29: 1102-1106
        • Rosenberg G.A.
        Matrix metalloproteinase-mediated neuroinflammation in vascular cognitive impairment of the binswanger type.
        Cell Mol Neurobiol. 2016; 36: 195-202
        • Wallin A.
        • Kapaki E.
        • Boban M.
        • et al.
        Biochemical markers in vascular cognitive impairment associated with subcortical small vessel disease - a consensus report.
        BMC Neurol. 2017; 17 (Article number: 102)
        • Hosoki S.
        • Tanaka T.
        • Ihara M.
        Diagnostic and prognostic blood biomarkers in vascular dementia: from the viewpoint of ischemic stroke.
        Neurochem Int. 2021; 146: 105015
        • Cipollini V.
        • Trolli F.
        • Giubilei F.
        Emerging biomarkers in vascular cognitive impairment and dementia: from pathophysiological pathways to clinical application.
        Int J Mol Sci. 2019; 20: 2812
        • Gorelick P.B.
        • Scuteri A.
        • Black S.E.
        • et al.
        Vascular contributions to cognitive impairment and dementia.
        Stroke. 2011; 42: 2672-2713
        • Von Cederwald B.F.
        • Josefsson M.
        • Wahlin A.
        • et al.
        Association of cardiovascular risk trajectory with cognitive decline and incident dementia.
        Neurology. 2022; 98: e2013-e2022
      1. MARKVCID website.
        (Available at:) (Accessed July 12, 2022)
        • Grill J.D.
        • Karlawish J.
        Disclosing Alzheimer disease biomarker results to research participants.
        JAMA Neurol. 2022; 79: 645-646
        • Scheltens P.
        • De Strooper B.
        • Kivipelto M.
        • et al.
        Alzheimer’s disease.
        Lancet. 2021; 397: 1577-1590
        • Ossenkoppele R.
        • van der Kant R.
        • Hansson O.
        Tau biomarkers in Alzheimer’s disease: toward implementation in clinical practice and trials.
        Lancet Neurol. 2022; 21: 726-734
        • Jack Jr., C.R.
        • Wiste H.J.
        • Therneau T.M.
        • et al.
        Associations of amyloid, tau, and neurodegeneration biomarker profiles with rates of memory decline among individuals without dementia.
        JAMA. 2019; 321: 2316-2325
        • Duzel E.
        • Ziegler G.
        • Berron D.
        • et al.
        Amyloid pathology but not APOE e4status is permissive for tau-related hippocampal dysfunction.
        Brain. 2022; 145: 1473-1485
        • Sullivan K.J.
        • Blackshear C.
        • Simino J.
        • et al.
        Association of midlife plasma amyloid-beta levels with cognitive impairment in late life.
        Neurology. 2021; 97: e1123-e1131
        • Janelidze S.
        • Teunlssen C.E.
        • Zetterberg H.
        • et al.
        Head-to-head comparison of 8 plasma amyloid-beta 42/40 assays in Alzheimer’s disease.
        JAMA Neurol. 2021; 78: 1375-1382
        • Delaby C.
        • Estelles T.
        • Zhu N.
        • et al.
        Alzheimer’s Res Ther. 2022; 14: 20https://doi.org/10.1186/s13195-022-00967-z
        • Meyer P.-F.
        • Ashton N.-J.
        • Karikari T.-K.
        • et al.
        Plasma p-tau231, p-tau 181, PET biomarkers, and cognitive change in older adults.
        Ann Neurol. 2022; 91: 548-560
        • Grothe M.J.
        • Moscoso A.
        • Ashton N.J.
        • et al.
        Associations of fully automated CSF and novel plasma biomarkers with Alzheimer’s disease neuropathology at autopsy.
        Neurology. 2021; 97: e1229-e1242
        • Head E.
        • Zetterberg H.
        Commentary on Oeckl et al., “Serum Beta-Synuclein is Higher in Down’s Syndrome and Precedes Rise of pTau181”.
        Ann Neurol. 2022; 92: 3-5
        • Fohner A.E.
        • Bartz T.M.
        • Tracy R.P.
        • et al.
        Association of serum neurofilament light chain concentration and MRI findings in older adults. The Cardiovascular Health Study.
        Neurology. 2022; 98: e903-e911
        • Schindler S.E.
        • Bateman R.J.
        Combining blood-based biomarkers to predict risk for Alzheimer’s disease dementia.
        Nat Aging. 2021; 1: 26-28
        • Ebernau J.L.
        • Pelkmans W.
        • Verberk I.M.W.
        • et al.
        Association of CSF, plasma, and imaging markers of neurodegeneration with clinical progression in people with subjective cognitive impairment.
        Neurology. 2022; 98: e1315-e1326
        • Stevenson-Hoare J.
        • Heslegrave A.
        • Leonenko G.
        • et al.
        Plasma biomarkers and genetics in the diagnosis and prediction of Alzheimer’s disease.
        Brain. 2022; (Online ahead of print): awac128https://doi.org/10.1093/brain/awac128
        • Caselli R.J.
        • Beach T.G.
        • Knopman D.S.
        • et al.
        Alzheimer's disease: scientific breakthroughs and translational challenges.
        Mayo Clin Proc. 2017; 92: 978-994
        • Conole E.L.S.
        • Stevenson A.J.
        • Maniega S.M.
        • et al.
        DNA methylation and protein markers of chronic inflammation and their associations with brain and cognitive aging.
        Neurology. 2021; 97: e2340-e2352
        • Bellenguez C.
        • Kucukali F.
        • Jansen I.E.
        • et al.
        New insights into the genetic etiology of Alzheimer’s disease and related dementias.
        Nat Genet. 2022; 54: 412-436
        • Yang A.C.
        • Vest R.T.
        • Kern F.
        • et al.
        A human brain vascular atlas reveals diverse mediators of Alzheimer’s risk.
        Nature. 2022; 603: 885-892
        • Amini S.
        • Hao B.
        • Zhang L.
        • et al.
        Automated detection of mild cognitive impairment and dementia from voice recordings: a natural language processing approach.
        Alzheimer’s Dement. 2022; : 1-10https://doi.org/10.1002/alz.12721
        • Dubois B.
        • Villain N.
        • Frisoni G.B.
        • et al.
        Clinical diagnosis of Alzheimer’s disease: recommendations of the international working group.
        Lancet Neurol. 2021; 20: 484-496